Pleiotropic Benefits of DPP-4 Inhibitors Beyond Glycemic Control

© The Author(s) 2021..

Dipeptidyl peptidase (DPP)-4 inhibitors are oral anti-diabetic medications that block the activity of the ubiquitous enzyme DPP-4. Inhibition of this enzyme increases the level of circulating active glucagon-like peptide (GLP)-1 secreted from L-cells in the small intestine. GLP-1 increases the glucose level, dependent on insulin secretion from pancreatic β-cells; it also decreases the abnormally increased level of glucagon, eventually decreasing the blood glucose level in patients with type 2 diabetes. DPP-4 is involved in many physiological processes other than the degradation of GLP-1. Therefore, the inhibition of DPP-4 may have numerous effects beyond glucose control. In this article, we review the pleiotropic effects of DPP-4 inhibitors beyond glucose control, including their strong beneficial effects on the stress induced accelerated senescence of vascular cells, and the possible clinical implications of these effects.

Medienart:

E-Artikel

Erscheinungsjahr:

2021

Erschienen:

2021

Enthalten in:

Zur Gesamtaufnahme - volume:14

Enthalten in:

Clinical medicine insights. Endocrinology and diabetes - 14(2021) vom: 12., Seite 11795514211051698

Sprache:

Englisch

Beteiligte Personen:

Kang, Seon Mee [VerfasserIn]
Park, Jeong Hyun [VerfasserIn]

Links:

Volltext

Themen:

DPP-4 inhibitors
Journal Article
Pleiotropic effects
Review
Senescence
Vascular cell

Anmerkungen:

Date Revised 05.11.2021

published: Electronic-eCollection

Citation Status PubMed-not-MEDLINE

doi:

10.1177/11795514211051698

funding:

Förderinstitution / Projekttitel:

PPN (Katalog-ID):

NLM332712184